Tofacitinib, an oral Janus kinase inhibitor: analysis of malignancies across the rheumatoid arthritis clinical development programme
Published 2015 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Tofacitinib, an oral Janus kinase inhibitor: analysis of malignancies across the rheumatoid arthritis clinical development programme
Authors
Keywords
-
Journal
ANNALS OF THE RHEUMATIC DISEASES
Volume 75, Issue 5, Pages 831-841
Publisher
BMJ
Online
2015-04-23
DOI
10.1136/annrheumdis-2014-205847
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- The effect of tofacitinib on pneumococcal and influenza vaccine responses in rheumatoid arthritis
- (2015) Kevin L Winthrop et al. ANNALS OF THE RHEUMATIC DISEASES
- Evaluation of the effect of tofacitinib on measured glomerular filtration rate in patients with active rheumatoid arthritis: results from a randomised controlled trial
- (2015) Joel M Kremer et al. ARTHRITIS RESEARCH & THERAPY
- Potential Mechanisms Leading to the Abnormal Lipid Profile in Patients With Rheumatoid Arthritis Versus Healthy Volunteers and Reversal by Tofacitinib
- (2015) Christina Charles-Schoeman et al. Arthritis & Rheumatology
- FRI0256 Long-term safety of tocilizumab in patients with rheumatoid arthritis following a mean treatment duration of 3.9 years
- (2014) M. Genovese et al. ANNALS OF THE RHEUMATIC DISEASES
- The JAK inhibitor tofacitinib suppresses synovial JAK1-STAT signalling in rheumatoid arthritis
- (2014) D L Boyle et al. ANNALS OF THE RHEUMATIC DISEASES
- Subcutaneous Abatacept for the Treatment of Rheumatoid Arthritis: Longterm Data from the ACQUIRE Trial
- (2014) M. C. Genovese et al. JOURNAL OF RHEUMATOLOGY
- Safety and Efficacy of Tofacitinib, an Oral Janus Kinase Inhibitor, for the Treatment of Rheumatoid Arthritis in Open-label, Longterm Extension Studies
- (2014) J. Wollenhaupt et al. JOURNAL OF RHEUMATOLOGY
- Tofacitinib versus Methotrexate in Rheumatoid Arthritis
- (2014) Eun Bong Lee et al. NEW ENGLAND JOURNAL OF MEDICINE
- Tofacitinib in Combination With Nonbiologic Disease-Modifying Antirheumatic Drugs in Patients With Active Rheumatoid Arthritis
- (2013) Joel Kremer et al. ANNALS OF INTERNAL MEDICINE
- Update on the safety profile of certolizumab pegol in rheumatoid arthritis: an integrated analysis from clinical trials
- (2013) V P Bykerk et al. ANNALS OF THE RHEUMATIC DISEASES
- Open-label tofacitinib and double-blind atorvastatin in rheumatoid arthritis patients: a randomised study*
- (2013) Iain B McInnes et al. ANNALS OF THE RHEUMATIC DISEASES
- Tofacitinib (CP-690,550) in patients with rheumatoid arthritis receiving methotrexate: Twelve-month data from a twenty-four-month phase III randomized radiographic study
- (2013) Désirée van der Heijde et al. ARTHRITIS AND RHEUMATISM
- Golimumab in Patients with Active Rheumatoid Arthritis Despite Methotrexate Therapy: Results Through 2 Years of the GO-FORWARD Study Extension
- (2013) E. C. Keystone et al. JOURNAL OF RHEUMATOLOGY
- Safety of Abatacept Administered Intravenously in Treatment of Rheumatoid Arthritis: Integrated Analyses of up to 8 Years of Treatment from the Abatacept Clinical Trial Program
- (2013) M. E. Weinblatt et al. JOURNAL OF RHEUMATOLOGY
- Tofacitinib (CP-690,550) in combination with methotrexate in patients with active rheumatoid arthritis with an inadequate response to tumour necrosis factor inhibitors: a randomised phase 3 trial
- (2013) Gerd R Burmester et al. LANCET
- Golimumab in patients with active rheumatoid arthritis who have previous experience with tumour necrosis factor inhibitors: results of a long-term extension of the randomised, double-blind, placebo-controlled GO-AFTER study through week 160
- (2012) Josef S Smolen et al. ANNALS OF THE RHEUMATIC DISEASES
- Long-term safety of rituximab in rheumatoid arthritis: 9.5-year follow-up of the global clinical trial programme with a focus on adverse events of interest in RA patients
- (2012) Ronald F van Vollenhoven et al. ANNALS OF THE RHEUMATIC DISEASES
- Adalimumab: long-term safety in 23 458 patients from global clinical trials in rheumatoid arthritis, juvenile idiopathic arthritis, ankylosing spondylitis, psoriatic arthritis, psoriasis and Crohn's disease
- (2012) Gerd R Burmester et al. ANNALS OF THE RHEUMATIC DISEASES
- Placebo-Controlled Trial of Tofacitinib Monotherapy in Rheumatoid Arthritis
- (2012) Roy Fleischmann et al. NEW ENGLAND JOURNAL OF MEDICINE
- Tofacitinib or Adalimumab versus Placebo in Rheumatoid Arthritis
- (2012) Ronald F. van Vollenhoven et al. NEW ENGLAND JOURNAL OF MEDICINE
- Malignancies associated with tumour necrosis factor inhibitors in registries and prospective observational studies: a systematic review and meta-analysis
- (2011) X. Mariette et al. ANNALS OF THE RHEUMATIC DISEASES
- A phase IIb dose-ranging study of the oral JAK inhibitor tofacitinib (CP-690,550) versus placebo in combination with background methotrexate in patients with active rheumatoid arthritis and an inadequate response to methotrexate alone
- (2011) Joel M. Kremer et al. ARTHRITIS AND RHEUMATISM
- Risk of non-melanoma skin cancer in a national cohort of veterans with rheumatoid arthritis
- (2011) Wassila Amari et al. RHEUMATOLOGY
- Phase II study of tofacitinib (CP-690,550) combined with methotrexate in patients with rheumatoid arthritis and an inadequate response to methotrexate
- (2011) Yoshiya Tanaka et al. ARTHRITIS CARE & RESEARCH
- Environment, inflammation, and cancer
- (2010) Pasquale Sansone et al. CURRENT OPINION IN GENETICS & DEVELOPMENT
- Pharmacologic Immunomodulation and Cutaneous Malignancy in Rheumatoid Arthritis, Psoriasis, and Psoriatic Arthritis
- (2010) M. S. KRATHEN et al. JOURNAL OF RHEUMATOLOGY
- Cancer risk with tumor necrosis factor alpha (TNF) inhibitors: meta-analysis of randomized controlled trials of adalimumab, etanercept, and infliximab using patient level data
- (2010) Johan Askling et al. PHARMACOEPIDEMIOLOGY AND DRUG SAFETY
- The safety and efficacy of a JAK inhibitor in patients with active rheumatoid arthritis: Results of a double-blind, placebo-controlled phase IIa trial of three dosage levels of CP-690,550 versus placebo
- (2009) Joel M. Kremer et al. ARTHRITIS AND RHEUMATISM
- Malignancies in the rheumatoid arthritis abatacept clinical development programme: an epidemiological assessment
- (2008) T A Simon et al. ANNALS OF THE RHEUMATIC DISEASES
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started